Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms

Abstract excerpt

With improved understanding of the epigenetic alterations underlying cancer development, numerous novel agents targeting pathways involved in epigenetic modifications and transcription including bromodomain inhibitors are under active investigation. We aim to discuss epigenetic modulation with a focus on bromodomain extra-terminal inhibitors (BETi) in the treatment of myeloid neoplasms. Since the first...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Histone Deacetylase Inhibitors Research
• Share to Protein Degradation and Inhibitors